The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Open accessAbstract
BACKGROUND: The hemolytic-uremic syndrome consists of the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal failure. The common form of the syndrome is triggered by infection with Shiga toxin-producing bacteria and has a favorable outcome. The less common form of the syndrome, called atypical hemolytic-uremic syndrome, accounts for about 10% of cases, and patients with this form of the syndrome have a poor prognosis. Approximately half of the patients with atypical hemolytic-uremic syndrome have mutations in genes that regulate the complement system. Genetic factors in the remaining cases are unknown. We studied the role of thrombomodulin, an endothelial glycoprotein with anticoagulant, antiinflammatory, and cytoprotective properties, in atypical hemolytic-uremic syndrome. METHODS: We sequenced the entire thrombomodulin gene (THBD) in 152 patients with atypical hemolytic-uremic syndrome and in 380 controls. Using purified proteins and cell-expression systems, we investigated whether thrombomodulin regulates the complement system, and we characterized the mechanisms. We evaluated the effects of thrombomodulin missense mutations associated with atypical hemolytic-uremic syndrome on complement activation by expressing thrombomodulin variants in cultured cells. RESULTS: Of 152 patients with atypical hemolytic-uremic syndrome, 7 unrelated patients had six different heterozygous missense THBD mutations. In vitro, thrombomodulin binds to C3b and factor H (CFH) and negatively regulates complement by accelerating factor I-mediated inactivation of C3b in the presence of cofactors, CFH or C4b binding protein. By promoting activation of the plasma procarboxypeptidase B, thrombomodulin also accelerates the inactivation of anaphylatoxins C3a and C5a. Cultured cells expressing thrombomodulin variants associated with atypical hemolytic-uremic syndrome had diminished capacity to inactivate C3b and to activate procarboxypeptidase B and were thus less protected from activated complement. CONCLUSIONS: Mutations that impair the function of thrombomodulin occur in about 5% of patients with atypical hemolytic-uremic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L., Palevsky, P., & workgroup, T. A. (2004) · Critical Care · doi:10.1186/cc2872 · Cited by 6,781
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132
Moake, J. L. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020528 · Cited by 1,221
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Self-citationDysfunction of Endothelial Protein C Activation in Severe Meningococcal Sepsis
Faust, S. N., Levin, M., Harrison, O. B., Goldin, R. D., Lockhart, M. S., Kondaveeti, S., Laszik, Z., Esmon, C. T., & Heyderman, R. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450603 · Cited by 690
Self-citationPurification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor
Bajzar, L., Manuel, R., & Nesheim, M. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.24.14477 · Cited by 680
Noris, M., & Remuzzi, G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100861 · Cited by 635
Self-citationSaito, H., Maruyama, I., Shimazaki, S., Yamamoto, Y., Aikawa, N., Ohno, R., Hirayama, A., Matsuda, T., Asakura, H., Nakashima, M., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02267.x · Cited by 603
Mutations in Complement Factor I Predispose to Development of Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Kemp, E. J., Mayland, E., Winney, R. J., Duffield, J. S., Warwick, G., Richards, A., Ward, R., Goodship, J. A., & Goodship, T. H. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010103 · Cited by 475
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationSyndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Self-citationOverview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864
Self-citationSchwartz, J., Padmanabhan, A., Aqui, N., Balogun, R. A., Connelly‐Smith, L., Delaney, M., Dunbar, N. M., Witt, V., Wu, Y., & Shaz, B. H. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21470 · Cited by 793
Practice parameter for the diagnosis and management of primary immunodeficiency
Bonilla, F. A., Khan, D. A., Ballas, Z. K., Chinen, J., Frank, M. M., Hsu, J. T., Keller, M., Kobrynski, L. J., Komarow, H. D., Mazer, B., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.04.049 · Cited by 791
Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationConnelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Schwartz, J., Winters, J. L., Padmanabhan, A., Balogun, R. A., Delaney, M., Linenberger, M. L., Szczepiorkowski, Z. M., Williams, M. E., Wu, Y., & Shaz, B. H. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21276 · Cited by 603
Cross Talk Pathways Between Coagulation and Inflammation
Foley, J. H., & Conway, E. M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306853 · Cited by 589
Self-citationEndothelium—role in regulation of coagulation and inflammation
van Hinsbergh, V. W. M. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0285-5 · Cited by 588
Fakhouri, F., Zuber, J., Frémeaux-Bacchi, V., & Loirat, C. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30062-4 · Cited by 571
Szczepiorkowski, Z. M., Winters, J. L., Bandarenko, N., Kim, H. C., Linenberger, M. L., Marques, M. B., Sarode, R., Schwartz, J., Weinstein, R., & Shaz, B. H. (2010) · Journal of Clinical Apheresis · doi:10.1002/jca.20240 · Cited by 508
Endothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
Licht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., et al. (2015) · Kidney International · doi:10.1038/ki.2014.423 · Cited by 420
Self-citationManthiram, K., Zhou, Q., Aksentijevich, I., & Kastner, D. L. (2017) · Nature Immunology · doi:10.1038/ni.3777 · Cited by 399
STEC-HUS, atypical HUS and TTP are all diseases of complement activation
Noris, M., Mescia, F., & Remuzzi, G. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.195 · Cited by 383
Self-citationThrombotic Microangiopathy and the Kidney
Brocklebank, V., Wood, K. M., & Kavanagh, D. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00620117 · Cited by 373
Bresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Pinto, S., Goodship, T. H. J., Alberti, M., Ribes, D., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090884 · Cited by 352
Self-citationSignaling pathways and intervention therapies in sepsis
Zhang, Y.-Y., & Ning, B.-T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00816-9 · Cited by 349
Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Goodship, T. H., & Richards, A. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.003 · Cited by 348
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy
Noris, M., Galbusera, M., Gastoldi, S., Macor, P., Banterla, F., Bresin, E., Tripodo, C., Bettoni, S., Donadelli, R., Valoti, E., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558296 · Cited by 341
Self-citationThrombomodulin and its role in inflammation
Conway, E. M. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0282-8 · Cited by 322
Self-citationMaga, T. K., Nishimura, C. J., Weaver, A. E., Frees, K. L., & Smith, R. J. H. (2010) · Human Mutation · doi:10.1002/humu.21256 · Cited by 308
Greenbaum, L. A., Fila, M., Ardissino, G., Al-Akash, S. I., Evans, J., Henning, P., Lieberman, K. V., Maringhini, S., Pape, L., Rees, L., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.11.026 · Cited by 296
Jokiranta, T. S. (2017) · Blood · doi:10.1182/blood-2016-11-709865 · Cited by 280
Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review
Joseph, A., Cointe, A., Mariani Kurkdjian, P., Rafat, C., & Hertig, A. (2020) · Toxins · doi:10.3390/toxins12020067 · Cited by 278
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272
ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
Zheng, X. L. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-013241 · Cited by 264
Complement factor H related proteins (CFHRs)
Skerka, C., Chen, Q., Fremeaux-Bacchi, V., & Roumenina, L. T. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.06.001 · Cited by 264
Diseases of complement dysregulation-an overview
Wong, E. K. S., & Kavanagh, D. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0663-8 · Cited by 115
Neuropathologic evidence of endothelial changes in cerebral small vessel disease
Giwa, M. O., Williams, J., Elderfield, K., Jiwa, N. S., Bridges, L. R., Kalaria, R. N., Markus, H. S., Esiri, M. M., & Hainsworth, A. H. (2012) · Neurology · doi:10.1212/wnl.0b013e3182407968 · Cited by 112
Gavriilaki, E., Anagnostopoulos, A., & Mastellos, D. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00337 · Cited by 106
The Role of Plasmapheresis in Critical Illness
Nguyen, T. C., Kiss, J. E., Goldman, J. R., & Carcillo, J. A. (2012) · Critical Care Clinics · doi:10.1016/j.ccc.2012.04.009 · Cited by 83
Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases
Recalde, S., Tortajada, A., Subias, M., Anter, J., Blasco, M., Maranta, R., Coco, R., Pinto, S., Noris, M., García-Layana, A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050580 · Cited by 32
Self-citation
Metadata
- Authors
- Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., Zoja, C., Remuzzi, G., & Conway, E. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-07-23
- Volume
- 361
- Issue
- 4
- Pages
- 345-357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2008607429
- Cited by
- 554
- References
- 45
- FWCI
- 16.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.